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Abstract
Background: Fascioliasis is a worldwide parasitic disease of domestic animals caused by helminths of the genus Fasciola. In
many parts of the world, particularly in poor rural areas where animal disease is endemic, the parasite also infects humans.
Adult parasites reside in the bile ducts of the host and therefore diagnosis of human fascioliasis is usually achieved by
coprological examinations that search for parasite eggs that are carried into the intestine with the bile juices. However,
these methods are insensitive due to the fact that eggs are released sporadically and may be missed in low-level infections,
and fasciola eggs may be misclassified as other parasites, leading to problems with specificity. Furthermore, acute clinical
symptoms as a result of parasites migrating to the bile ducts appear before the parasite matures and begins egg laying. A
human immune response to Fasciola antigens occurs early in infection. Therefore, an immunological method such as ELISA
may be a more reliable, easy and cheap means to diagnose human fascioliasis than coprological analysis.
Methodology/Principal findings: Using a panel of serum from Fasciola hepatica-infected patients and from uninfected
controls we have optimized an enzyme-linked immunosorbent assay (ELISA) which employs a recombinant form of the
major F. hepatica cathepsin L1 as the antigen for the diagnosis of human fascioliasis. We examined the ability of the ELISA
test to discern fascioliasis from various other helminth and non-helminth parasitic diseases.
Conclusions/Significance: A sensitive and specific fascioliasis ELISA test has been developed. This test is rapid and easy to
use and can discriminate fasciola-infected individuals from patients harbouring other parasites with at least 99.9% sensitivity
and 99.9% specificity. This test will be a useful standardized method not only for testing individual samples but also in mass
screening programs to assess the extent of human fascioliasis in regions where this zoonosis is suspected.
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Introduction
Fascioliasis, or liver fluke disease, is a food-borne infection
caused by trematodes of the genus Fasciola. The disease has been
traditionally viewed as of mainly veterinary importance because of
the substantial production and economic losses it causes in
livestock, particularly sheep and cattle. In contrast, human
fascioliasis has until recently been neglected by the medical
community. Due to its increased spread and chronic nature, it is
now recognized as a disease of global human concern by the
(WHO) [1–3]. Studies indicate that approximately 17 million
people are infected with Fasciola and 91.1 million are living at risk
of infection [4].
Fasciola hepatica has a worldwide distribution and causes major
health problems in Europe (Portugal, France and Spain), the
Americas (Bolivia, Peru, Chile, Ecuador and Venezuela), Cuba
and Oceania and overlaps with F. gigantica in many areas of
Africa and Asia [5]. Interestingly, high prevalence in humans
does not appear to be related to high prevalence in livestock, so
that the expected correlation between animal and human
fascioliasis is not a consistent finding [6]. On the other hand,
Fasciola gigantica, in humans was thought to be of relatively little
importance due to its low incidence in endemic areas. However,
since fascioliasis is not a reportable disease in many countries,
the number of cases (.500) reported in the literature represent
the tip of the iceberg [7,8].
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F. hepatica tolerates a wide range of environmental conditions
and has a remarkable ability to adapt to new hosts [9] and thus has
a wide host range [5]. This has led to its spread from its original
location in pre-domestication of animals and more recently over
the five continents due to the export of European livestock during
colonization [10]. The spread of F. hepatica is also related to the
geographic expansion of its original intermediate host, the snail
Galba truncatula. By contrast, the smaller geographic distribution of
F. gigantica seems to be related to the weaker diffusion capacity of
its intermediate snail hosts (African Radix natalensis and the
Eurasian Radix auricularia) [6]. The most commonly affected are
farm animals (eg, sheep and cattle). Nevertheless, it can infect a
variety of wild animals (eg, deer, llamas, kangaroos, rabbits,
beavers, and rats) which shows the remarkable capability of the
parasite to adapt to new hosts [6,9].
Infections in animals and humans occur when vegetation or
water contaminated with infective encysted dormant larvae
(metacercariae) is ingested. The parasites excyst in the host
intestine, migrate through the intestinal wall into the peritoneal
cavity and then into the liver parenchyma where they caused
extensive tissue damage and blood vessel hemorrhaging repre-
senting the acute phase of the disease [11]. After eight to twelve
weeks post infection the parasites move into the biliary passages,
become sexually mature and start producing eggs [9]. The
parasites become obligate blood feeders on host haemoglobin to
support the production of eggs and access the blood by puncturing
the bile ducts wall [12]. Fasciola spp. have been estimated to
produce 20 000 to 50 000 eggs per fluke per day in animals [13].
Up to 50% of F. hepatica infections are asymptomatic and disease
may appear anywhere from a few days to several years after
infection thereby making the diagnosis challenging [14]. Human
fascioliasis is routinely diagnosed by the detection of parasite eggs
in the feces. These can only be detected after the parasite has
matured in the bile ducts and released eggs that are carried into
the intestine with the bile juices. However, this coprological
method presents several drawbacks: First, bile juices are irregularly
released into the intestine and therefore more than one samples
needs to be assessed. Second, in low level infections the fluke eggs
are often not found in the feces, even after multiple fecal
examinations [15]. Third, since eggs are produced by mature
adults in the bile ducts, the acute phase of the disease is are not
identified.
Enzyme-linked immunosorbent assay (ELISA) methods devel-
oped for determination of anti-Fasciola antibodies provide an
alternative to coprological examination. Anti-F. hepatica antibodies
can be found after 2–4 weeks post-infection providing a means for
early detection of disease using parasite extracts or excretory-
secretory (FhES) products as antigen [16]. Cathepsin Ls proteases
(FhCL), the most predominant component of FhES have been
employed for the development of enzyme linked immunosorbant
assays (ELISA) and proven to be highly effective in a number of
diagnostic studies performed in our laboratory in the past few
years [17–19]. FhCL1 was initially purified from ES antigens by
Smith and others [20] and shown to be released by vesicles
synthesized by the intestinal cells of the liver fluke [21] indicating a
role in the digestion of ingested blood and tissues. The protease is
also likely to have a role in assisting the parasites’ migration
through the host’s tissues [22] since it is capable of degrading the
extracellular matrix and basal membrane components and may
also have a role in evasion of immune response since it can cleave
host immunoglobulins and prevent attachment of immune effector
cells to newly excysted juveniles (infective larvae) [20,23].
Previous studies used native FhCL1 or an enzymatically active
recombinant rFhCL1. However these were prone to breakdown
and auto-catalytic degradation during purification and also
cleaved immunoglobulin in the ELISA. We have therefore
employed an inactive recombinant FhCL1 variant (FhCL1Gly26).
We also employed more recently developed and commercially
available secondary antibodies against anti-total IgG and several
subclasses (IgG1, IgG2 and IgG4) to screen and optimize the test
using a panel of serum samples well-characterized Fasciola-
infected patients. The test we developed is easy to use and can
discriminate fasciola-infected individuals from patients harbouring
other parasites with 99.9% sensitivity and 99.9% specificity. This
ELISA will be a useful standardized method not only for testing
individual samples but can be employed in mass screening
programs to assess the extent of human fascioliasis in regions
where this zoonosis is suspected.
Materials and Methods
Reagents
High protein-binding 96-well polystyrene microtiter plates were
purchased from Thermo Fischer Scientific Inc. (Cat #3455,
Ontario Canada), Peroxidase-conjugated labeled anti-human
immunoglobulin IgG (Goat) was from Perkin Elmer (Cat
#NEF802, Massachusetts, USA). The substrate 3,39,5,59-Tetra-
methylbenzidine (TMB/E) was purchased from Millipore (Cat #
ES001-500 ml, Massachusetts, USA). Peroxidase-conjugated anti-
human immunoglobulin IgG1, IgG2 and IgG4 were purchased
from Southern Biotech (Cat # 9052-5, 9060-05, 9190-05
respectively, Birmingham, Alabama, USA).
Clinical samples
The human Fasciola samples were reviewed and approved by
the ‘Pedro Kourı´’ Tropical Medicine Institute (IPK, Havana City,
Cuba) Biomedical Research Ethics Board. The human control and
other parasitic diseases sera were obtained from the Passive
Parasitic Diseases Surveillance System diagnostic testing at the
National Reference Laboratory for Parasitology (NRCP; Mon-
treal, Quebec, Canada) and were considered exempt. All samples
used in this study were anonymized. These consisted of samples
Author Summary
Fascioliasis is a food-borne human disease caused by
helminth parasites of the genus Fasciola. It is a global
disease of domestic animals but its increased recognition
as a major zoonosis has led to the World Health
Organization including fascioliasis on the list of important
human parasitic diseases. Current diagnosis of human
fascioliasis involves the detection of eggs in the stool.
However, eggs are not observed during the acute phase
when the parasite is migrating through the tissues, and
can be missed during the chronic phase when parasites
are in the bile duct due to the sporadic release of the bile
into the intestines. Using a panel of serum from Fasciola
hepatica-infected patients, we have optimized an enzyme-
linked immunosorbent assay (ELISA) which employs a
recombinant form of the major F. hepatica cathepsin L1 as
the antigen for the diagnosis of human fascioliasis. The
test is easy to use and can discriminate fasciola-infected
individuals from patients harbouring other parasites with
99.9% sensitivity and 99.9% specificity. This ELISA will be a
useful standardized method not only for testing individual
samples but also in mass screening programs to assess the
extent of human fascioliasis in regions where this zoonosis
is suspected.
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from 93 Cuban individuals that were coprologically-positive for
eggs of F. hepatica and clinically diagnosed in the hospital, samples
from 72 Cuban and 63 Canadian individuals that were shown to
be negative for Fasciola infection, and 158 serum samples obtained
from individuals infected with other parasitic diseases including,
amoebiasis (12), ascariasis (10), Chagas disease (10), cysticercosis
(10), echinococosis (13), enterobiasis (2), filariasis (11), giardiasis (5),
leishmaniasis (9), malaria (14), metorchiasis (9), schistosomiasis (9) ,
strongyloidiasis (6), toxocariasis (14), toxoplasmosis (13), and
trichinellosis (11).
Expression and purification of FhCL1
The full length F. hepatica preprocathepsin L1 cDNA was
previously cloned in our laboratory into a P. pastoris multicopy
system using P. pastoris GS115 strain and pPIC9K vector (26). The
variant FheproCL1Gly26 (Cys26 to Gly26) was used in this study
and expressed as described by Collins et al. (21). The inactive
enzyme was produced by fermentation at 30uC and 250 rpm in
1 liter BMGY broth buffered to pH 6.0 into 4 liter baffled flasks
until an OD600 of 2–6 was achieved. The cells were centrifuged at
3,0006 g for 10 minutes at room temperature and the induction
initiated by resuspending the pellets in 200 ml BMMY broth and
adding 1% of filter–sterilized 100% methanol every 24 hours for 3
days. The culture was then centrifuged at 16,0006 g for
30 minutes at room temperature. The pellets were discarded
and FhCL1 isolated from the supernatant by Ni-NTA affinity
chromatography as previously described [17,18].
Optimization and development of the enzyme-linked
immunosorbent assay (ELISA)
For the purpose of optimizing the ELISA a pool of serum from
fasciola-infected individuals (30) and of negatives controls (30) was
prepared. Determination of the optimum antigen concentration
and the dilution of the sample serum and secondary conjugated
antibody that gave the most superior background-to-signal ratio
were assessed by employing a matrix formation. Using different
96-well plates, each with a constant antigen concentration,
different dilutions of the pooled positive control serum was added
to the wells from top to bottom (well A–G) while different dilutions
of the secondary antibody were tested in duplicate from left to
right (wells 1–12). All optimization experiments were repeated at
least once.
For each plate FhCL1 antigen was dissolved in bicarbonate/
carbonate coating buffer at pH 9.0. One hundred microliters of
the solution was then added to each well and incubated
overnight at 4uC. After washing four times, excess protein
binding sites were blocked at 37uC for 1 h by adding 100 ml of
2% bovine serum albumin diluted in PBS/0.1% Tween 20.
After a further washing procedure, 100 ml of pooled samples
sera (diluted at 1:100, 1:200, 1:400 and 1:800) were added and
the plate incubated for 1 h at 37uC. Following another wash,
100 ml of peroxidase-conjugated anti-human IgG (diluted
1:4000, 1:8000, 1:12000, 1:16000 and 1:32000) was added to
the wells and the plates were incubated for 30 min at 37uC.
After a final washing step bound antibodies were detected by the
addition of 100 ml of TMB. The color was developed for 10 min
and the reaction was stopped with 50 ml of 0.1 M sulphuric
acid. The plates were read on an ELISA plate reader at 405 nm.
All serum samples were analyzed for the binding of total IgG
and IgG1, IgG2 or IgG4 using the appropriate secondary
monoclonal antibodies specific for each. Results are reported as
the mean values obtained from three independent experiments
conducted in duplicate.
Statistical analysis
Box-Cox transformation of the data from uninfected control for
IgG showed that lambda of 0.33 minimized skewness in the data.
Data was therefore transformed by cube-rooting to normalize the
distribution prior to statistical analysis [24]. A standard deviation
for the uninfected controls and for the fascioliasis positive was
determined from the transformed data and a cut-off limit for
sensitivity and specificity in the assay set at t-standard deviations
from the mean for a one-tailed test with p = 0.0001. This was
converted back to the original units by cubing. Homogeneity of
variance was assessed by Levene’s test. Effect of infection on IgG
absorbance was assessed by Oneway ANOVA. The difference
between infected and control was assessed by post-hoc testing with
Dunnett’s test for each disease against the control, with a one-sided
test. All statistical analysis was carried out using SPSS version 17.
Differences between negative peaks were analyzed by the Mann-
Whitney U-Test. Normality was assessed by the Shapiro-Wilk test.
Results
Optimization of ELISA using cathepsin L1 for diagnosis of
Fascioliasis
To determine the optimal conditions for diagnosis of human
fascioliasis by ELISA using the FhCL1 as antigen we used a pool
of positive control sera from 20 Cuban patients with a known
infection with F. hepatica and a pool of sera from 20 Cuban patients
negative for this parasitic infection. We performed a matrix
comparison of ELISAs using various antigen concentrations,
dilutions of the pooled primary sera and dilutions of secondary
antibodies specific for different human antibody isotypes. The
ELISA conditions providing the best positive to negative signal
ratio and used in our subsequent studies were as follows: wells were
coated with 100 ml of 0.25 mg/ml of the FhCL1 antigen; the
dilution of the human primary sera used was 1/200 and the
dilution of the secondary antibody was 1/32000, 1/8000, 1/100
and 1/32000 for secondary antibodies anti-total IgG, anti-IgG1,
anti-IgG2 and anti-IgG4, respectively.
Validation of ELISA using FhCL1 for diagnosis of
Fascioliasis
A total of 386 serum samples were screened using our optimized
ELISA. Statistical analysis of the ELISA data was performed to
evaluate the efficacy of FhCL1 to discriminate between positive
infected individuals and negative non-infected individuals. First,
the results for assays using anti-total IgG as the secondary antibody
were plotted in a histogram to evaluate the distribution of the
population to be analyzed (Figure 1A). The data were normalized
for statistical analysis by cube rooting (Figure 1B). Using the
normalized data, the standard deviations for the negative and
positive peaks were calculated to establish the cut-off limit for the
sensitivity and specificity of the assay to detect non-infected and
infected individuals. The cut-off for the negatives for the
transformed data was therefore set at 0.82 OD units with
p = 0.0001 using a one-tailed test which separates 99.99% of the
uninfected patients to the left of the line and infected patients to
the right (black vertical dashed line in the histogram (Figure 1B).
This value was then converted back into the normal data and gave
a cut-off of 0.55 OD units (Figure 1A). The cut-off for the infected
positive patients was computed in the same manner as the negative
patients and gave a value of 0.58 OD units for the normal data
(data not shown in histogram). It can be observed in Figure 1A
that no Fasciola-negative patients fell to the right of the cut-off,
and no Fasciola-positives fell to the left. Therefore, not only did the
ELISA test using anti-total IgG secondary antibody give a 99.99%
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specificity but it also exhibited a .99.99% sensitivity for
identifying infected individuals.
Statistical analysis of the data obtained using anti-IgG4 as the
secondary antibody was also performed. The data was plotted into
a histogram and results analyzed. Two of the negatives samples do
not seem to belong to the distribution of the rest of the negatives
and are outside the cut-off that discriminate 99.99% of the
uninfected patients (Figure 2A). To group the entire Fasciola-
negative individuals together the cut-off limit was set just below the
positives at 0.1 OD units. The cut-off was set then at 4.2 OD units
standard deviations from the mean of the negative patients giving
a cut-off of 0.1 OD units (p = 0.0001) that provided a 99.99%
discrimination between positives and negatives. When we plotted
the positives and negatives patients on a histogram a large spread
of positives was observed and only a spike for negatives was found
(the values for negatives are very low) (Figure 2B). However, while
we found that using anti-IgG4 secondary antibodies had the
potential to discriminate between positives and negative infected
patients, the gap between these was very small (this cannot be fully
appreciated in the graph shown in Figure 2B as the bars divided by
the dashed cut-off line lie next to each other) and therefore more
probability of error.
When we employed secondary antibodies specific for IgG1 and
IgG2 in our ELISA assays the sensitivity and specificity dropped
drastically compared to anti-total IgG and anti-IgG4. For these
assays we found that the data was badly skewed from a normal
distribution and a clear cut-off between the negative and positive
patient sera could not be established. Thus a definitive distinction
of non-infected and infected patients could not be made
(Figure 3A, 3B and 3C).
Figure 1. Analysis of ELISA results using FhCL1 antigen and anti-total-IgG as secondary antibody. A) Histogram of control and Fasciola-
positive serum samples. B) Histogram of normalized total IgG for negative control and Fasciola positive samples. Dash line represents cut-off for
negative samples.
doi:10.1371/journal.pntd.0002414.g001
Figure 2. Sensitivity and specificity analysis for ELISA using anti-IgG4 as secondary antibody. A) Histogram showing negative sample
where two fall out of the cut-off limit. B) Histogram showing Fasciola-positive and control negative sera. Discrimination between negatives and
positives exists; however, a small space exists between them that cannot be noticed from the graph. Dashed line represents the cut-off for negatives
sample.
doi:10.1371/journal.pntd.0002414.g002
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Comparison of isotypes in FhCL1 ELISAs using
scattergraphs
To visualize the difference between the results obtained for the
various specific isotypes more clearly, we compared the data using
scattergraphs. It can be seen in Figure 4A that for IgG4 some
space separated the F. hepatica negative and positive patients
although the gap was small, as found with the histogram. Both
anti-IgG1 and anti-IgG2 were even less effective with a large
overlap between the Fasciola-negatives giving the highest readings
and the Fasciola-positives giving the lowest readings (Figure 4B
and C). Using these latter two secondary antibodies it seems
inevitable that we could get many of false positives and negatives.
Figure 5 shows a comparison between the data using anti-total
IgG secondary antibody with the other secondary antibodies and
summarizes the results. The results from fasciola-infected (positive)
and non-infected (control) sera for each secondary antibody were
plotted separately. It is clear that using anti-total IgG provides best
discrimination between positives and negative samples. While the
difference between the mean values for the positive and negative
samples was wider when anti-IgG4 was used in the assays, the
spread of readings obtained for the positive samples reduced the
ability to distinguish between the borderline cases and the negative
patients compare to anti-total IgG. The overlap of positives and
negatives was even more pronounced when anti-IgG1 and IgG2
alone were applied.
Figure 3. Analysis of ELISA data using FhCL1 antigen and
secondary antibodies specific for IgG1, IgG2 and IgG4+IgG1
isotypes. Histograms of ELISA data obtained for Fasciola-positive and
control patient sera using A) anti-IgG1, B) anti-IgG2, and C) IgG4+IgG1
secondary antibodies. Black bars represent sera from control patients
while white bars represent sera from positive patients.
doi:10.1371/journal.pntd.0002414.g003
Figure 4. Scattergraphs for ELISA data using various secondary
antibodies. Data obtained using secondary antibodies specific for
anti-IgG4 (A), anti-IgG2 (B) and anti-IgG1 (C) compared to data obtained
using anti-total IgG. Blue circles represent sera from control patients
while green circles represent Fasciola-positive patients.
doi:10.1371/journal.pntd.0002414.g004
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Analysis of sera from various parasitic infections in FhCL1
ELISAs
To examine if cross-reactivity of our ELISA using recombinant
FhCL1 for the detection of human fascioliasis was evident, we
performed assays using fasciola-infected patient sera (93 infected
Cubans) and non-infected (72 Cubans and 63 Canadians) and
compared these with sera obtained from patients infected with
range of other worm as described above. We used anti-total IgG
and anti-IgG4 as the secondary antibodies (Figure 6).
The result showed that absorbance readings obtained with sera
from patients infected with parasites other than F. hepatica closely
matched that obtained with the negative control samples. We
Figure 5. Comparison of ELISA data obtained using secondary antibodies specific for various isotypes. Absorbance between positive
infected sera and negative control sera using anti-total IgG and the different serotypes.
doi:10.1371/journal.pntd.0002414.g005
Figure 6. Box plots of ELISA data using sera from non-infected control patients, F. hepatica-infected patients, and patients with
various parasitic diseases. A: ELISA using anti-total IgG as secondary antibody and B: ELISA using anti-IgG4 as secondary antibody. The dashed
line represents the cut-off for negative samples. Results are obtained from three independent experiments conducted in duplicate.
doi:10.1371/journal.pntd.0002414.g006
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found that using 0.55 OD units as cut-off with anti-total IgG as
secondary antibody, the test can discriminate between F. hepatica
patients and all other infections examined (Figure 6A). Using
Oneway ANOVA we found a very highly significant effect of
treatment (disease) (p,0.0005), and post-hoc comparison of all
parasitic diseases compared to the negative controls using
Dunnet’s test showed that none of these had a significantly
greater IgG value than the controls except for fascioliasis using
one-tailed test at 0.01% level. These results revealed two
homogeneous populations within the data and suggest a very
high level of confidence for distinguishing between F. hepatica
and the other diseases tested. Thus, no evidence of cross-
reactivity was observed (table 1). A similar analysis was
computed with the data obtained with anti-IgG4 using a 0.1A
OD units cut-off line. Fasciola positives can be differentiated
from controls and all other infections, although the discrimina-
tion between these was smaller when compared with the anti-
total IgG data (Figure 6B).
Discussion
Previous studies in our laboratory have shown the potential of
F.hepatica cathepsin L1 antigen to detect Fascioliasis with high
confidence [17–19,25]. However, in these studies we employed
either a native form of cathepsin L1 isolated from the secretory
products of the parasite or an enzymatically active recombinant
cathepsin L1 expressed in Saccharomyces cerevisiae. However, in the
present report we used recombinant cathepsin L1 expressed in
the yeast Pichia pastoris and purified to high homogeneity as
previously reported [18]. Most importantly, this recombinant
contained a single amino acid substitution, replacing the active
site Cys25 with Gly, with a consequential ablation of functional
activity without altering conformation [26] which made the
enzyme much more stable in the fermentation and downstream
isolation process. Furthermore, because active cathepsin L1 can
cleave antibody molecules [6,25,27] this modification ensured
that the enzyme did not degrade primary and secondary
antibodies used in the ELISA.
In our present study we have also optimized the ELISA assay to
increase accuracy and reliability. Previous ELISA assays were
performed using biotin- conjugated anti-human IgG to detect
bound primary antibody followed by anti-human immunoglobulin
conjugated with avidin before the substrate ABTS (2,29-Azinobis
[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) was
added [18]. The availability of new reagents (HRP-conjugated
secondary antibody) have improved the sensitivity of the test, and
at the same time decreased the number of steps required and, thus,
the work-load and expense.
Optimization of the ELISA was performed by using a pool of
sera from patients infected with F. hepatica (diagnosed by eggs in
stool) and a pool of negative sera from matched non-infected
patients. The optimization of the ELISA allowed us to determine
the best dilution of the primary sera and secondary antibody to
obtain an excellent discrimination between positives and negatives
using secondary antibodies that detected total IgG and IgG4.
Either of these reagents could be used to diagnose individuals, as
proven in previous studies [17,18], a conclusion supported by the
correlation between total IgG and IgG4 depicted in scattergraphs
(Figure 4A). Anti-IgG4 exhibited lower background (very low
absorbance in Fasciola negative individuals) compared with anti-
total IgG; however, statistical analysis illustrated a broader gap
between seropositives and seronegatives when using anti-total IgG
secondary antibodies which ensures less probability of false-
positives or false-negatives.
When using anti-IgG4 as the secondary antibody, two patients
(seronegative by anti-total IgG and egg count) appeared as
borderline cases; these did not group to the normal seronegative
distribution and were beyond the cut-off. In an attempt to include
them in the seronegative group the cut off was set at 0.1 OD units
and consequently we obtained a narrower gap between positive
and negative groups compared to anti-total IgG.
Previous studies by O’Neill et al. [18] had shown that by
employing anti-IgG4 secondary antibodies led to an improved
discrimination between seropositives and seronegatives com-
pared with anti-total IgG. Our contrary results may be
explained by the fact that helminthic infections increase anti-
IgG4 antibodies in correlation with intensity [27–30] and these
individuals in the borderline might be at an initial stage of
infection or the burden of parasite is low; however, this cannot
be ascertained because we do not possess the precise infection
levels of the Fasciola-infected individuals from our panel (only
presence or absence of eggs were determined). Furthermore, the
samples used by O’Neill et al. [18] were obtained from the field
and analyzed by anti-IgG4 ELISA using native cathepsin L1.
This was a blind study using volunteers in Bolivia which
undoubtedly harboured different intensities of infection where
the cut-off is more difficult to determine. In the present study we
used sera from who had been clinically diagnosed fascioliasis
and would therefore have had a high level of infection, and long
term infection. This clear distinction between Fasciola positive/
negative allowed us to more robustly calculate a cut-off line. It is
also possible that different results can be obtained depending on
the population of subjects examined. Nevertheless, both the
present study and that of O’Neill et al [18] shows that using
anti-total IgG provides sufficiently accurate results to consider it
the most optimal secondary antibody to use.
We also analyzed the data derived from ELISAs that employed
secondary antibodies specific to IgG1 and IgG2 isotypes.
Table 1. Absorbance values of total IgG.
Group N of individuals Mean Std. Deviation
Control 135 0.134 0.065
Positives 93 1.780 0.374
Amoebiasis 12 0.200 0.054
Ascariasis 10 0.214 0.063
Chagas disease 10 0.210 0.076
Cysticercosis 10 0.170 0.059
Echinoccocosis 13 0.174 0.067
Enterobiasis 2 0.170 0.091
Filariasis 11 0.086 0.033
Giardiasis 5 0.199 0.037
Leishmaniasis 9 0.211 0.109
Malaria 14 0.179 0.066
Metorchiasis 9 0.216 0.096
Schistosomiais 9 0.147 0.045
Strongyloidiasis 6 0.184 0.057
Toxocariasis 14 0.191 0.089
Toxoplasmosis 13 0.214 0.096
Trichinellosis 11 0.085 0.052
Results are obtained from three independent experiments conducted in
duplicate.
doi:10.1371/journal.pntd.0002414.t001
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However, these secondary reagents did not perform satisfactorily
and several patients were misdiagnosed. An increase in the
background was observed when using anti-IgG1 and not all
Fasciola-infected patients produce IgG1 antibodies. This resulted
in an overlapping of some Fasciola-negative and Fasciola-positive
sera decreasing the sensitivity and specificity of the test consider-
ably. This was not surprising due to the fact that Fasciola infection
induces the production of IgG4 followed by IgG1 and to a lesser
extent IgG2 and IgG3 [27].
Sera sample from patients infected with other diseases were used
to evaluate cross-reactivity in our ELISA. Analysis of cross-
reactivity is extremely important since fascioliasis is a world-
wide parasitic disease which can co-exist with other human
parasitic diseases which can complicate diagnosis. Furthermore,
current parasitological methods depend on the expertise of the
worker because F. hepatica eggs can be confused with eggs from
other helminths. Therefore, a good diagnostic test needs to be
able to distinguish between Fasciola and other parasitic
diseases. We screened human samples infected with different
parasitic diseases and analyzed the ELISA data statistically.
Using our ELISAs no cross-reactivity with other parasitic
diseases was observed; in fact, the mean absorbances observed
for the various diseases examined were not significantly
different from the non-infected negative controls patients
regardless of whether we employed anti-total IgG or anti-
IgG4 secondary antibodies. Moreover, all the Fasciola-infected
individuals had significantly higher absorbance readings than
those obtained from patients infected with the other parasites.
This is consistent with previous studies using native cathepsin
L1 [18]. However, we found that anti-total IgG secondary
antibody performed slightly better than anti-IgG4 as judged by
the gap size between fasciola-positives and fasciola-negatives
when the cut off was set.
Over the last two decades there has been a renewed interest in
human fascioliasis. This is due to the increase in epidemiological
surveys that has revealed the present emergence/re-emergence of
the disease both in humans and animals in many regions [26].
Studies have shown that human fascioliasis presents marked
heterogeneity, including different epidemiological situations and
transmission patterns in different endemic areas [1]. The negative
impact of fascioliasis on human communities demands rapid
action [2]. Sensitive and specific diagnostic tools are necessary in
order to determine the full extent of infections is regions such as
Iran, South America and Egypt where animal and human
fascioliasis are endemic so that patients can be treated before
clinical complications appear.
Here, we have produced a standardized test using a highly
stable recombinant form of cathepsin L1, FhCL1, which exhibits
high sensitivity and specificity and with no cross-reaction with
other parasitic diseases. High production of this enzyme can be
obtained by purification of P. pastoris culture medium allowing us
to provide sufficient quantities of material to supply diagnostic
centers for mass screening in regions where human fascioliasis is
prevalent.
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